Sugi Predict

Sugi Predict / Compounds / SCHEMBL29953208

SCHEMBL29953208

SCHEMBL29953208

N#Cc1cnccc1B(O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 1/20 0.42
▸ NCOA3 Q9Y6Q9 1/20 0.39
▸ KMT2A Q03164 2/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ CCNT1 O60563 1/20 0.35
▸ CDK9 P50750 1/20 0.35
▸ HASPIN Q8TF76 1/20 0.35
▸ ELANE P08246 2/20 0.35
▸ GRM1 Q13255 1/20 0.34
▸ CLK1 P49759 2/20 0.34
▸ CLK2 P49760 2/20 0.34
▸ DYRK1A Q13627 2/20 0.34
▸ CLK4 Q9HAZ1 2/20 0.34
▸ DYRK1B Q9Y463 2/20 0.34
▸ CLK3 P49761 1/20 0.34
▸ CDK5 Q00535 1/20 0.34
▸ CDK5R1 Q15078 1/20 0.34
▸ HIPK2 Q9H2X6 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4359777 1.00 HTT (0.42) HTTNCOA3KMT2AMEN1ALDH1A1
SCHEMBL520070 0.84 HTT (0.42) HTTNCOA3KMT2AMEN1ALDH1A1
SCHEMBL13798615 0.82 HDAC8 (0.38) HDAC8
SCHEMBL17099864 0.77 LATS1 (0.33) HTTNCOA3KMT2AMEN1ELANE
SCHEMBL29546988 0.73 HTT (0.50) HTTNCOA3KMT2AMEN1ALDH1A1
SCHEMBL20043 0.73 HTT (0.50) HTTNCOA3KMT2AMEN1ALDH1A1
SCHEMBL211613 0.72 — —
SCHEMBL166277 0.72 — —
SCHEMBL30360459 0.72 — —
SCHEMBL2928918 0.72 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12410183-B2 Sars-cov2 main protease inhibitors GILEAD SCIENCES, INC. (US) 2025-09-09 — — US disclosed
US-20250042915-A1 SARS-COV2 MAIN PROTEASE INHIBITORS GILEAD SCIENCES, INC. 2025-02-06 — — US disclosed
US-12091420-B2 SARS-COV2 main protease inhibitors GILEAD SCIENCES, INC. (US) 2024-09-17 — — US disclosed
US-20240239807-A1 SARS-COV2 MAIN PROTEASE INHIBITORS GILEAD SCIENCES, INC. 2024-07-18 — — US disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250042915-A1 SARS-COV2 MAIN PROTEASE INHIBITORS ACE2, TMPRSS2, ACE HTT 3577/4885NCOA3 1606/4885KMT2A 3085/4885
US-12091420-B2 SARS-COV2 main protease inhibitors ACE2, TMPRSS2, ACE HTT 3577/4885NCOA3 1606/4885KMT2A 3085/4885
US-12410183-B2 Sars-cov2 main protease inhibitors ACE2, TMPRSS2, ACE HTT 3577/4885NCOA3 1606/4885KMT2A 3085/4885
US-20240239807-A1 SARS-COV2 MAIN PROTEASE INHIBITORS ACE2, TMPRSS2, ACE HTT 3577/4885NCOA3 1606/4885KMT2A 3085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.